Grants and Contributions:
Title:
Development and Characterization of Next-Generation Antibody Candidates with Enhanced Selectivity
Agreement Number:
1039167
Agreement Value:
$360,000.00
Agreement Date:
Jan 5, 2026 - Nov 20, 2026
Description:
A key challenge in cancer and autoimmune disease treatment is precisely targeting diseased tissues while sparing healthy cells. The project advances antibody therapeutics to meet this challenge.
Organization:
National Research Council Canada
Expected Results:
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Location:
Montreal, Quebec, CA H3B 2E3
Reference Number:
172-2025-2026-Q4-1039167
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
778015800
Recipient Type:
For-profit organization
Recipient's Legal Name:
Ability Biotherapeutics Inc.
Federal Riding Name:
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number:
24077
Program:
Industrial Research Assistance Program
Program Purpose:
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Coverage:
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity.
NAICS Code:
541710